Ultragenyx Pharmaceutical Inc. (RARE) Form 8-K — Oct 14, 2026
Ultragenyx Pharmaceutical agreed on October 8, 2026 to sell its Rare Pediatric Disease Priority Review Voucher for $203 million in cash at closing. The PRV was awarded by the FDA on September 17, 2026 following approval of FAYUVITM (UX111) for pediatric MPS IIIA (Sanfilippo syndrome Type A).
Key figures
- Deal Value Usd
- 203000000
- Asset sold
- Rare Pediatric Disease Priority Review Voucher (PRV)
- Prv award date
- 2026-09-17
- Fda approval product
- FAYUVITM (rebisufligene etisparvovec-hopf, UX111)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.